{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:57:03Z","timestamp":1790848623605,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10067-022-06415-5","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T05:02:37Z","timestamp":1666242157000},"page":"621-632","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-7396","authenticated-orcid":false,"given":"Durga Prasanna","family":"Misra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6196-9198","authenticated-orcid":false,"given":"Gaurav","family":"Pande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4508-1233","authenticated-orcid":false,"given":"Vikas","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"6415_CR1","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::Aid-art5>3.0.Co;2-w","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552\u20131563. https:\/\/doi.org\/10.1002\/1529-0131(199809)41:9%3c1552::Aid-art5%3e3.0.Co;2-w","journal-title":"Arthritis Rheum"},{"key":"6415_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G, Sebba A, Gu J et al (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 69:88\u201396. https:\/\/doi.org\/10.1136\/ard.2008.105197","journal-title":"Ann Rheum Dis"},{"key":"6415_CR3","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","volume":"58","author":"EH Choy","year":"2018","unstructured":"Choy EH (2018) Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford) 58:953\u2013962. https:\/\/doi.org\/10.1093\/rheumatology\/key339","journal-title":"Rheumatology (Oxford)"},{"key":"6415_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S et al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367:508\u2013519. https:\/\/doi.org\/10.1056\/NEJMoa1112072","journal-title":"N Engl J Med"},{"key":"6415_CR5","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC et al (2017) Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 76:1340\u20131347. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210322","journal-title":"Ann Rheum Dis"},{"key":"6415_CR6","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O et al (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377:1537\u20131550. https:\/\/doi.org\/10.1056\/NEJMoa1615975","journal-title":"N Engl J Med"},{"key":"6415_CR7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1112168","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Ghosh S, Panes J et al (2012) Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367:616\u2013624. https:\/\/doi.org\/10.1056\/NEJMoa1112168","journal-title":"N Engl J Med"},{"key":"6415_CR8","doi-asserted-by":"publisher","unstructured":"Moriana C, Moulinet T, Jaussaud R, Decker P (2022) JAK inhibitors and systemic sclerosis: a systematic review of the literature. Autoimmun Rev 21:103168. https:\/\/doi.org\/10.1016\/j.autrev.2022.103168","DOI":"10.1016\/j.autrev.2022.103168"},{"key":"6415_CR9","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","volume":"12","author":"SA Hasni","year":"2021","unstructured":"Hasni SA, Gupta S, Davis M et al (2021) Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun 12:3391. https:\/\/doi.org\/10.1038\/s41467-021-23361-z","journal-title":"Nat Commun"},{"key":"6415_CR10","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1136\/annrheumdis-2021-220484","volume":"80","author":"Y Liu","year":"2021","unstructured":"Liu Y, Ji Z, Yu W et al (2021) Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study. Ann Rheum Dis 80:1631\u20131633. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220484","journal-title":"Ann Rheum Dis"},{"key":"6415_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10067-021-05973-4","volume":"41","author":"U Rathore","year":"2022","unstructured":"Rathore U, Thakare DR, Patro P, Agarwal V, Sharma A, Misra DP (2022) A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis. Clin Rheumatol 41:33\u201344. https:\/\/doi.org\/10.1007\/s10067-021-05973-4","journal-title":"Clin Rheumatol"},{"key":"6415_CR12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386:316\u2013326. https:\/\/doi.org\/10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"key":"6415_CR13","unstructured":"US FDA warning on 1st September 2021. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death. Accessed 4 Aug\u00a02022"},{"key":"6415_CR14","unstructured":"Delong C, Preuss CV (2022) Black box warning. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9, StatPearls Publishing LLC.; 2022."},{"key":"6415_CR15","unstructured":"EMA starts review of Janus kinase inhibitor safety. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/janus-kinase-inhibitors-jaki-article-20-referral-review-started_en.pdf. Accessed 4 Aug\u00a02022"},{"key":"6415_CR16","unstructured":"Prescribing information for tofacitinib from the US FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf. Accessed 14 Aug\u00a02022"},{"key":"6415_CR17","unstructured":"US FDA warning on 25th February (2019)\u00a0https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/safety-trial-finds-risk-blood-clots-lungs-and-death-higher-dose-tofacitinib-xeljanz-xeljanz-xr. Accessed 4 Aug\u00a02022"},{"key":"6415_CR18","unstructured":"US FDA warning on 26th July (2019)\u00a0https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and. Accessed 4 Aug\u00a02022"},{"key":"6415_CR19","unstructured":"Pfizer announces results of ORAL Surveillance trial. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-co-primary-endpoint-results-post-marketing. Accessed 5 Aug\u00a02022"},{"key":"6415_CR20","unstructured":"US FDA warning on 4th February (2021)\u00a0https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis. Accessed 4 Aug\u00a02022"},{"key":"6415_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","volume":"46","author":"C Charles-Schoeman","year":"2016","unstructured":"Charles-Schoeman C, Wicker P, Gonzalez-Gay MA et al (2016) Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum 46:261\u2013271. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.05.014","journal-title":"Semin Arthritis Rheum"},{"key":"6415_CR22","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1002\/art.40911","volume":"71","author":"C Charles-Schoeman","year":"2019","unstructured":"Charles-Schoeman C, DeMasi R, Valdez H et al (2019) Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol 71:1450\u20131459. https:\/\/doi.org\/10.1002\/art.40911","journal-title":"Arthritis Rheumatol"},{"key":"6415_CR23","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","volume":"79","author":"P Mease","year":"2020","unstructured":"Mease P, Charles-Schoeman C, Cohen S et al (2020) Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis 79:1400\u20131413. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216761","journal-title":"Ann Rheum Dis"},{"key":"6415_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr2.11232","volume":"3","author":"JM Kremer","year":"2021","unstructured":"Kremer JM, Bingham CO 3rd, Cappelli LC et al (2021) Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. ACR Open Rheumatol 3:173\u2013184. https:\/\/doi.org\/10.1002\/acr2.11232","journal-title":"ACR Open Rheumatol"},{"key":"6415_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/rheumatology\/keab294","volume":"61","author":"RJ Desai","year":"2021","unstructured":"Desai RJ, Pawar A, Khosrow-Khavar F, Weinblatt ME, Kim SC (2021) Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (Oxford) 61:121\u2013130. https:\/\/doi.org\/10.1093\/rheumatology\/keab294","journal-title":"Rheumatology (Oxford)"},{"key":"6415_CR26","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","volume":"81","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ (2022) Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis 81:798\u2013804. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221915","journal-title":"Ann Rheum Dis"},{"key":"6415_CR27","doi-asserted-by":"publisher","unstructured":"Fang YF, Liu JR, Chang SH, Kuo CF, See LC (2022) Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis. Int J Rheum Dis. Epub ahead of print. https:\/\/doi.org\/10.1111\/1756-185x.14414","DOI":"10.1111\/1756-185x.14414"},{"key":"6415_CR28","doi-asserted-by":"publisher","unstructured":"Bilgin E, Duran E, \u00dcnald\u0131 E, Kalyoncu U, Kiraz S, Ertenli \u0130 (2022) Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single centre observational study. Rheumatology (Oxford) 61:e267\u2013e269. https:\/\/doi.org\/10.1093\/rheumatology\/keac226","DOI":"10.1093\/rheumatology\/keac226"},{"key":"6415_CR29","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00296-017-3844-9","volume":"37","author":"K Kume","year":"2017","unstructured":"Kume K, Amano K, Yamada S et al (2017) Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study. Rheumatol Int 37:2079\u20132085. https:\/\/doi.org\/10.1007\/s00296-017-3844-9","journal-title":"Rheumatol Int"},{"key":"6415_CR30","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jaad.2016.06.012","volume":"75","author":"JJ Wu","year":"2016","unstructured":"Wu JJ, Strober BE, Hansen PR et al (2016) Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis. J Am Acad Dermatol 75:897\u2013905. https:\/\/doi.org\/10.1016\/j.jaad.2016.06.012","journal-title":"J Am Acad Dermatol"},{"key":"6415_CR31","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","volume":"11","author":"R Wolk","year":"2017","unstructured":"Wolk R, Armstrong EJ, Hansen PR et al (2017) Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis. J Clin Lipidol 11:1243\u20131256. https:\/\/doi.org\/10.1016\/j.jacl.2017.06.012","journal-title":"J Clin Lipidol"},{"key":"6415_CR32","doi-asserted-by":"publisher","unstructured":"Sleutjes JAM, Roeters van Lennep JE, van der Woude CJ, de Vries AC (2022) Lipid changes after induction therapy in patients with inflammatory bowel disease: effect of different drug classes and inflammation. Inflamm Bowel Dis. Online ahead of print. https:\/\/doi.org\/10.1093\/ibd\/izac100","DOI":"10.1093\/ibd\/izac100"},{"key":"6415_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","volume":"18","author":"BE Sands","year":"2020","unstructured":"Sands BE, Taub PR, Armuzzi A et al (2020) Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis. Clin Gastroenterol Hepatol 18:123-132.e123. https:\/\/doi.org\/10.1016\/j.cgh.2019.04.059","journal-title":"Clin Gastroenterol Hepatol"},{"key":"6415_CR34","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/acr2.11166","volume":"2","author":"CT Ritchlin","year":"2020","unstructured":"Ritchlin CT, Giles JT, Ogdie A et al (2020) Tofacitinib in patients with psoriatic arthritis and metabolic syndrome: a post hoc analysis of phase 3 studies. ACR Open Rheumatol 2:543\u2013554. https:\/\/doi.org\/10.1002\/acr2.11166","journal-title":"ACR Open Rheumatol"},{"key":"6415_CR35","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jid.2017.08.040","volume":"138","author":"J Kim","year":"2018","unstructured":"Kim J, Tomalin L, Lee J et al (2018) Reduction of inflammatory and cardiovascular proteins in the blood of patients with psoriasis: differential responses between tofacitinib and etanercept after 4 weeks of treatment. J Invest Dermatol 138:273\u2013281. https:\/\/doi.org\/10.1016\/j.jid.2017.08.040","journal-title":"J Invest Dermatol"},{"key":"6415_CR36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/fcp.12731","volume":"36","author":"P Totoson","year":"2022","unstructured":"Totoson P, Peyronnel C, Quiri\u00e9 A et al (2022) Tofacitinib improved peripheral endothelial dysfunction and brain-derived neurotrophic factor levels in the rat adjuvant-induced arthritis model. Fundam Clin Pharmacol 36:363\u2013374. https:\/\/doi.org\/10.1111\/fcp.12731","journal-title":"Fundam Clin Pharmacol"},{"key":"6415_CR37","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1093\/eurheartj\/ehab447","volume":"42","author":"C Baldini","year":"2021","unstructured":"Baldini C, Moriconi FR, Galimberti S, Libby P, De Caterina R (2021) The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. Eur Heart J 42:4389\u20134400. https:\/\/doi.org\/10.1093\/eurheartj\/ehab447","journal-title":"Eur Heart J"},{"key":"6415_CR38","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40841","volume":"71","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Weinblatt ME, Burmester GR et al (2019) Cardiovascular Safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol 71:1042\u20131055. https:\/\/doi.org\/10.1002\/art.40841","journal-title":"Arthritis Rheumatol"},{"key":"6415_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12944-019-0994-7","volume":"18","author":"C Qiu","year":"2019","unstructured":"Qiu C, Zhao X, She L et al (2019) Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Lipids Health Dis 18:54. https:\/\/doi.org\/10.1186\/s12944-019-0994-7","journal-title":"Lipids Health Dis"},{"key":"6415_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC, Takeuchi T, Burmester GR et al (2022) Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis 81:335\u2013343. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221276","journal-title":"Ann Rheum Dis"},{"key":"6415_CR41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40259-018-0304-3","volume":"32","author":"F Huang","year":"2018","unstructured":"Huang F, Luo ZC (2018) Risk of adverse drug events observed with baricitinib 2 mg versus baricitinib 4 mg once daily for the treatment of rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. BioDrugs 32:415\u2013423. https:\/\/doi.org\/10.1007\/s40259-018-0304-3","journal-title":"BioDrugs"},{"key":"6415_CR42","unstructured":"US FDA prescribing information for baricitinib. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207924s006lbl.pdf. Accessed 19 Sept\u00a02022"},{"key":"6415_CR43","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40264-020-01036-w","volume":"44","author":"PG Conaghan","year":"2021","unstructured":"Conaghan PG, Mysler E, Tanaka Y et al (2021) Upadacitinib in rheumatoid arthritis: a benefit-risk assessment across a phase III program. Drug Saf 44:515\u2013530. https:\/\/doi.org\/10.1007\/s40264-020-01036-w","journal-title":"Drug Saf"},{"key":"6415_CR44","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2021","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL et al (2021) Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 80:304\u2013311. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218510","journal-title":"Ann Rheum Dis"},{"key":"6415_CR45","doi-asserted-by":"publisher","unstructured":"Fleischmann R, Mysler E, Bessette L et al (2022) Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open 8:e002012. https:\/\/doi.org\/10.1136\/rmdopen-2021-002012","DOI":"10.1136\/rmdopen-2021-002012"},{"key":"6415_CR46","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1111\/1756-185x.14235","volume":"24","author":"X Zeng","year":"2021","unstructured":"Zeng X, Zhao D, Radominski SC et al (2021) Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy. Int J Rheum Dis 24:1530\u20131539. https:\/\/doi.org\/10.1111\/1756-185x.14235","journal-title":"Int J Rheum Dis"},{"key":"6415_CR47","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40744-021-00410-z","volume":"9","author":"GR Burmester","year":"2022","unstructured":"Burmester GR, Winthrop K, Blanco R et al (2022) Safety profile of upadacitinib up to 3 years in psoriatic arthritis: an integrated analysis of two pivotal phase 3 trials. Rheumatol Ther 9:521\u2013539. https:\/\/doi.org\/10.1007\/s40744-021-00410-z","journal-title":"Rheumatol Ther"},{"key":"6415_CR48","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40264-021-01067-x","volume":"44","author":"K Yamaoka","year":"2021","unstructured":"Yamaoka K, Tanaka Y, Kameda H et al (2021) The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Saf 44:711\u2013722. https:\/\/doi.org\/10.1007\/s40264-021-01067-x","journal-title":"Drug Saf"},{"key":"6415_CR49","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","volume":"78","author":"W Xie","year":"2019","unstructured":"Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z (2019) Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 78:1048\u20131054. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214846","journal-title":"Ann Rheum Dis"},{"key":"6415_CR50","doi-asserted-by":"publisher","first-page":"1759720x1989549","DOI":"10.1177\/1759720x19895492","volume":"11","author":"W Xie","year":"2019","unstructured":"Xie W, Xiao S, Huang Y, Sun X, Zhang Z (2019) Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis 11:1759720x198954925. https:\/\/doi.org\/10.1177\/1759720x19895492","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"6415_CR51","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L (2020) Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 158:1554-1573.e1512. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.001","journal-title":"Gastroenterology"},{"key":"6415_CR52","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/art.41580","volume":"73","author":"M Yates","year":"2021","unstructured":"Yates M, Mootoo A, Adas M et al (2021) Venous thromboembolism risk with JAK inhibitors: a meta-analysis. Arthritis Rheumatol 73:779\u2013788. https:\/\/doi.org\/10.1002\/art.41580","journal-title":"Arthritis Rheumatol"},{"key":"6415_CR53","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/rhu.0000000000001804","volume":"28","author":"C Alves","year":"2022","unstructured":"Alves C, Penedones A, Mendes D, Marques FB (2022) Risk of cardiovascular and venous thromboembolic events associated with Janus kinase inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis. J Clin Rheumatol 28:69\u201376. https:\/\/doi.org\/10.1097\/rhu.0000000000001804","journal-title":"J Clin Rheumatol"},{"key":"6415_CR54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/annrheumdis-2022-eular.879","volume":"81","author":"M Dougados","year":"2022","unstructured":"Dougados M, Charles-Schoeman C, Szekanecz Z et al (2022) OP0264 Impact of baseline cardiovascular risk on the incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme. Ann Rheum Dis 81:175. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.879","journal-title":"Ann Rheum Dis"},{"key":"6415_CR55","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1136\/annrheumdis-2022-eular.1180","volume":"81","author":"Z Szekanecz","year":"2022","unstructured":"Szekanecz Z, Giles JT, Buch MH et al (2022) POS0110 Incidence of major adverse cardiovascular events stratified by geographic region and baseline cardiovascular risk: a post hoc analysis of oral surveillance. Ann Rheum Dis 81:278. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.1180","journal-title":"Ann Rheum Dis"},{"key":"6415_CR56","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1136\/annrheumdis-2022-eular.1182","volume":"81","author":"MH Buch","year":"2022","unstructured":"Buch MH, Charles-Schoeman C, Curtis J et al (2022) POS0237 Major adverse cardiovascular events, malignancies and venous thromboembolism by baseline cardiovascular risk: a post hoc analysis of oral surveillance. Ann Rheum Dis 81:356. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.1182","journal-title":"Ann Rheum Dis"},{"key":"6415_CR57","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/annrheumdis-2022-eular.1234","volume":"81","author":"C Charles-Schoeman","year":"2022","unstructured":"Charles-Schoeman C, Buch MH, Dougados M et al (2022) POS0674 Risk factors for major adverse cardiovascular events in patients aged \u226550 years with rheumatoid arthritis and \u22651 additional cardiovascular risk factor: a post hoc analysis of oral surveillance. Ann Rheum Dis 81:611. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.1234","journal-title":"Ann Rheum Dis"},{"key":"6415_CR58","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1136\/annrheumdis-2022-eular.1255","volume":"81","author":"JT Giles","year":"2022","unstructured":"Giles JT, Charles-Schoeman C, Buch MH et al (2022) POS0520 Association between baseline statin treatment and major adverse cardiovascular events in patients with rheumatoid arthritis: a post hoc analysis of oral surveillance. Ann Rheum Dis 81:518. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.1255","journal-title":"Ann Rheum Dis"},{"key":"6415_CR59","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2022-eular.1238","volume":"81","author":"G Karpouzas","year":"2022","unstructured":"Karpouzas G, Szekanecz Z, Baecklund E et al (2022) POS0519 Relationship between disease activity and major adverse events in patients with rheumatoid arthritis on tofacitinib or TNF inhibitors: a post hoc analysis of oral surveillance. Ann Rheum Dis 81:517. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.1238","journal-title":"Ann Rheum Dis"},{"key":"6415_CR60","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/annrheumdis-2022-eular.1016","volume":"81","author":"C Charles-Schoeman","year":"2022","unstructured":"Charles-Schoeman C, Fleischmann RM, Mysler E et al (2022) POS0239 Risk of venous thromboembolic events in patients with rheumatoid arthritis aged \u226550 years with \u22651 cardiovascular risk factor: results from a phase 3b\/4 randomised study of tofacitinib vs tumour necrosis factor inhibitors. Ann Rheum Dis 81:358. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.1016","journal-title":"Ann Rheum Dis"},{"key":"6415_CR61","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/annrheumdis-2022-eular.787","volume":"81","author":"Z Szekanecz","year":"2022","unstructured":"Szekanecz Z, Charles-Schoeman C, Vranic I et al (2022) OP0269 Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. Ann Rheum Dis 81:179. https:\/\/doi.org\/10.1136\/annrheumdis-2022-eular.787","journal-title":"Ann Rheum Dis"},{"key":"6415_CR62","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.18553\/jmcp.2022.28.9.1046","volume":"28","author":"J Qian","year":"2022","unstructured":"Qian J, Xue X, Shannon J (2022) Characteristics of adverse event reporting of Xeljanz\/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration. J Manag Care Spec Pharm 28:1046\u20131052. https:\/\/doi.org\/10.18553\/jmcp.2022.28.9.1046","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06415-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06415-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06415-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T10:14:19Z","timestamp":1674555259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06415-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["6415"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06415-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"assertion":[{"value":"17 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Durga Prasanna Misra declares that he has no conflict of interest.Gaurav Pande declares that he has no conflict of interest.Vikas Agarwal declares that he has no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}